high5immunology.tv | Rheumatology | EULAR 2022

Spotlight Discussions RA – ENG

EULAR 2022

Prevention of RA possible by treating very early?

F. Behrens, P. Sewerin, E. Choy, T. Kvien, A. Balsa, A. Rubbert-Roth, A. Askari

EULAR 2022

The road of glucocorticoids in RA

F. Behrens, P. Sewerin, E. Choy, T. Kvien, A. Balsa, A. Rubbert-Roth, A. Askari

EULAR 2022

Updated EULAR RA recommendations: does it change the…

F. Behrens, P. Sewerin, E. Choy, T. Kvien, A. Balsa, A. Rubbert-Roth, A. Askari

Rheumatoid arthritis – ENG

Updated EULAR Recommendations RA, GLORIA

EULAR 2022

Rapid tapering of steroids - how quickly should we…

Ernest Choy, MD

EULAR 2022

The significance of depression and air pollution in…

Tore Kvien, MD

RA-BIODAM

EULAR 2022

Radiographic progression in RA patients in daily…

Andrea Rubbert-Roth, MD

TREAT EARLIER

EULAR 2022

Interest of methotrexate before the emergence of RA

Vincent Goëb, MD

EULAR 2022

HOT - Difficulties in treatment of RA

Alejandro Balsa, MD

TREAT EARLIER

EULAR 2022

Does MTX have a disease modifying effect in patients…

Tore Kvien, MD

ARIAA

EULAR 2022

Can early abatacept therapy in high-risk patients…

Andrea Rubbert-Roth, MD

ORAL Survaillance

EULAR 2022

Risk of venous thromboembolic events in ORAL…

Alejandro Balsa, MD

ORAL Surveillance

EULAR 2022

Analysis of baseline ORAL surveillance data: is it due…

Andrea Rubbert-Roth, MD

TREAT EARLIER

EULAR 2022

Double-blind placebo controlled trial of MTX in…

Alejandro Balsa, MD

Rheumatoid arthritis – GER/FRA/NOR/ESP

TREAT EARLIER

EULAR 2022

Metotrexate en pacientes con artralgia inflamatoria en…

Alejandro Balsa, MD

EULAR 2022

Abordaje de la artritis reumatoide difícil de tratar

Alejandro Balsa, MD

ARIAA

EULAR 2022

Frühzeitige Abatacept-Therapie bei Hochrisiko RA…

Andrea Rubbert-Roth, MD

TREAT EARLIER

EULAR 2022

Har MTX en sykdomsmodifiserende effekt hos pasienter…

Tore Kvien, MD

TREAT EARLIER

EULAR 2022

Interet du méthotrexate avant l´émergence de la PR

Vincent Goëb, MD

ORAL Surveillance

EULAR 2022

Liegt es an Vorgeschichte und oder Geographie?

Andrea Rubbert-Roth, MD

RA-BIODAM

EULAR 2022

Radiologische Progression ist unabhängig von…

Andrea Rubbert-Roth, MD

ORAL Survaillance

EULAR 2022

Riesgo de eventos tromboembolicos en el ORAL…

Alejandro Balsa, MD

EULAR 2022

Betydning av depresjon og luftforurensning hos…

Tore Kvien, MD

EULAR 2022

MRT auch ohne Kontrastmittel bei RA einsetzbar

Philipp Sewerin, MD

Spotlight Discussions SpA – ENG

EULAR 2022

New data on IL-17 inhibition and a 1st in class…

F. Behrens, V. Goëb, T. Kvien, P. Sewerin, F. Ciccia, E. Lubrano, A. Askari

EULAR 2022

The (unmet) need for perspective biomarkers in SpA

F. Behrens, V. Goëb, T. Kvien, P. Sewerin, F. Ciccia, E. Lubrano, A. Askari

EULAR 2022

Hot topic spine: axial diseases in SpA and suitable…

F. Behrens, V. Goëb, T. Kvien, P. Sewerin, F. Ciccia, E. Lubrano, A. Askari

Psoriatic arthritis – ENG

EULAR 2022

A new treatment for PsA

Ennio Lubrano, MD

EULAR 2022

Who has the best chance of being in prolonged remission…

Vincent Goëb, MD

EULAR 2022

New therapies for PsA

Ayman Askari, MD

EULAR 2022

Low rates of sustained remission in a real world…

Philipp Sewerin, MD

EULAR 2022

PsA is associated with a higher risk of hematological…

Philipp Sewerin, MD

ULTIMATE

EULAR 2022

Course of ultrasound-detected synovitis in PsA patients…

Philipp Sewerin, MD

EULAR 2022

First in class: new molecule to inhibit IL-17A

Frank Behrens, MD

EULAR 2022

Every joint counts! Even patients with LJC should be…

Frank Behrens, MD

EULAR 2022

Revival of leflunomide - the combination with MTX

Frank Behrens, MD

Discover/Cosmos

EULAR 2022

Guselkumab "more safe" than Placebo

Frank Behrens, MD

Psoriatic arthritis – FRA/GER/ITA

Discover/Cosmos

EULAR 2022

Guselkumab "sicherer" als Plazebo

Frank Behrens, MD

EULAR 2022

Jedes Gelenk zählt! Auch bei niedrigem Joint Count…

Frank Behrens, MD

EULAR 2022

Geringe Raten an anhaltender Remission im Real Wold…

Philipp Sewerin, MD

EULAR 2022

PsA mit einem höheren Risiko für hämatologische…

Philipp Sewerin, MD

EULAR 2022

Qui a le plus de chance d´etre en rémission prolongee…

Vincent Goëb, MD

EULAR 2022

Revival von Leflunomid - in Kombination mit MTX

Frank Behrens, MD

ULTIMATE

EULAR 2022

Verlauf von sonographischer Synovitis unter Secukinumab

Philipp Sewerin, MD

EULAR 2022

Novità nel trattamento dell’Artrite Psoriasica

Ennio Lubrano, MD

EULAR 2022

Neues Molekül zur Hemmung von IL-17A

Frank Behrens, MD

Axial spondyloarthritis – ENG

EULAR 2022

New ASAS/EULAR axSpA recommendations

Xabier Michelena Vegas, MD

EULAR 2022

Rates of progression from non-radiographic to…

Francesco Ciccia, MD

SELECT-AXIS 2, BE MOBILE 2

EULAR 2022

New drugs in axSpA

Xabier Michelena Vegas, MD

EULAR 2022

A deep dive review of axSpA

Ennio Lubrano, MD

EULAR 2022

Artificial intelligence in axSpA

Xabier Michelena Vegas, MD

Axial spondyloarthritis – ESP/ITA

EULAR 2022

Rivisitazione dell’impegno assiale dell'artrite…

Ennio Lubrano, MD

EULAR 2022

Percentuale di progressione da forma non radiografica a…

Francesco Ciccia, MD

EULAR 2022

Nuevos recomendaciones ASAS/EULAR en EspAax

Xabier Michelena Vegas, MD

EULAR 2022

Inteligencia artificial en EspAax

Xabier Michelena Vegas, MD

SELECT-AXIS 2, BE MOBILE 2

EULAR 2022

Nuevos terapias en EspAax

Xabier Michelena Vegas, MD

Lupus erythematosus – ENG

EULAR 2022

Deucravacitinib for Lupus Erythematosus - Phase II…

Bimba Franziska Hoyer, MD

AURORA-2

EULAR 2022

Voclosporin for Lupus Nephritis

Bimba Franziska Hoyer, MD

Lupus erythematosus – GER

AURORA-2

EULAR 2022

Voclosporin bei Lupus Nephritis

Bimba Franziska Hoyer, MD

EULAR 2022

TYK2-Inhibitor Deucravacitinib wirksam und verträglich

Bimba Franziska Hoyer, MD

COVID-19 – ENG

Nor-vaC study

EULAR 2022

Vaccination response against COVID-19 in patients with…

Tore Kvien, MD

EULAR 2022

Type of mRNA COVID-19 vaccine influences antibody…

Andrea Rubbert-Roth, MD

EULAR 2022

Predictive severity factors of COVID-19 in R-IMID…

Ayman Askari, MD

EULAR 2022

Vaccination in rheumatic diseases including COVID-19

Ayman Askari, MD

COVID-19 – GER/NOR

EULAR 2022

Antikörperkinetik unter verschiedenen…

Andrea Rubbert-Roth, MD

Nor-vaC study

EULAR 2022

Vaksine respons (COVID-19) hos pasienter med…

Tore Kvien, MD

Ankylosing spondylitis – ENG

EULAR 2022

GM-CSF is increased in patients with AS and persists…

Francesco Ciccia, MD

Ankylosing spondylitis – ITA

EULAR 2022

I livelli di GM-CSF sono incrementati nei pazienti con…

Francesco Ciccia, MD

VARIA Highlights – ENG

COMPACT

EULAR 2022

Real-world data of an etanercept biosimilar (GP2015) in…

Ayman Askari, MD

EULAR 2022

Link between biomechanical stretch and synovial…

Francesco Ciccia, MD

EULAR 2022

Management of calcific tendonitis by BARBOTAGE

Ayman Askari, MD

EULAR 2022

The microbiota to predict the response to the treatment…

Vincent Goëb, MD

EULAR 2022

New developments in the field of osteoarthristis

Ayman Askari, MD

EULAR 2022

Pain - challenges in clinical practice

Ayman Askari, MD

VARIA Highlights – FRA/ITA

EULAR 2022

Le microbiote pour prédire la réponse au traitement du…

Vincent Goëb, MD

EULAR 2022

Legame tra stress biomeccanico e infiammazione…

Francesco Ciccia, MD